Q4 2025 net sales reached $961 million, an increase of 6.2% (2.5% in constant currency) compared to Q4 2024. The company reported a Q4 2025 net loss of ($146) million and diluted loss per share of ($0.74), primarily due to ($144) million in goodwill and intangible impairments, net of tax. Q4 2025 adjusted EPS was $0.27, an increase from $0.26 in Q4 2024. Full year 2025 net sales were $3,680 million, a decrease of (3.0%) (4.3% in constant currency) from FY 2024. Full year 2025 reported net loss was ($598) million and diluted loss per share was ($3.00). Full year 2025 adjusted EPS was $1.60, a decrease from $1.67 in FY 2024. The company provided a full year 2026 outlook, projecting net sales in the range of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50. A restructuring initiative was announced, expected to redirect approximately $120 million annually into the Return-to-Growth Action Plan, focusing on innovation, clinical education, and sales team education. A new capital allocation strategy was initiated, eliminating the quarterly dividend to redeploy capital towards debt retirement and share repurchases. New agreements were established with Patterson Dental, Benco Dental, Burkhart Dental Supply, and A-dec. Dentsply Sirona launched the Surity Female External Catheter, entering a new market category in the U.S. Three new members were appointed to the Board of Directors: James Forbes, Brian McKeon, and Don Zurbay.